創造新機會：腫瘤XDC市場

XDC正在革新癌症治療，開啟精準治療、條件性活化和治療潛力的新篇章。然而，在快速發展、激烈競爭和不斷擴充的研發管線中，保持領先地位需要的不僅是洞察力，更需要前沿知識、策略遠見和數據驅動的決策。

光在2024/25年度，腫瘤研發管線就迎來了一波創新浪潮，預計將有436種新型XDC、超過972個藥物事件，以及涵蓋2505個藥物項目的共計10642個事件。這清晰地證明了該領域發展速度的加快和複雜性的增加。

隆重推出腫瘤XDC分析工具，這是一款全面的解決方案，可協助您駕馭這一充滿活力的領域，追蹤新興趨勢，並掌握突破性機會。

探索該領域奧秘的終極工具：

• XDC（藥物偶聯物）是一類多樣化且快速發展的癌症治療藥物，至少包含七種不同的形式：抗體藥物偶聯物 (ADC)、勝肽藥物偶聯物 (PDC)、小分子藥物偶聯物 (SMDC)、放射免疫偶聯物 (RDC)、寡核苷酸藥物偶聯物 (ODC)、奈米藥物偶聯物和酵素藥物偶聯物。這是一個充滿活力的研究領域，正在重塑精準癌症治療的模式。
• XDC 的有效載荷代表了腫瘤學中最有效且種類最豐富的藥物類別，包括微管抑制劑、DNA 損傷劑、拓樸異構酶抑制劑、放射性同位素、免疫調節劑和基因調節劑。 每種有效載荷都經過精心挑选和設計，旨在最大限度地殺傷腫瘤細胞，同時最大限度地減少全身暴露，因此有效載荷的創新是XDC領域治療效果和差異化的關鍵推動因素。
• 連接子技術是XDC性能的分子基石，它透過可裂解（pH敏感、酶敏感）和不可裂解連接子等創新技術，精確控制有效載荷的釋放。連接子的選擇直接影響穩定性、藥物動力學和腫瘤選擇性，為優化XDC平台的安全性、有效性和治療指數提供了策略性槓桿。
• 條件活化策略為XDC賦予了強大的精準性，透過低pH值、腫瘤相關酶、缺氧和氧化還原梯度等觸發因素，使有效載荷僅在腫瘤微環境中釋放。這種腫瘤選擇性活化最大限度地減少了脫靶效應，提高了治療指數，代表了更聰明、更安全的下一代藥物遞送方法。
• 雙特異性和多特異性抗體偶聯藥物（ADC）的出現標誌著標靶治療的新紀元，能夠同時活化多種腫瘤抗原和免疫效應路徑。這種方法增強了腫瘤選擇性，克服了抗原異質性，並為雙重有效載荷遞送和免疫系統調節開闢了新的機遇，使其處於XDC領域創新前沿。

其影響為何？快速擴展的臨床研發管線、突破性的FDA批准以及激增的投資機會，使XDC領域成為當今腫瘤學領域最令人振奮的前沿領域之一。

六大突破性優勢：

"腫瘤學XDC分析工具" 的功能

• 競爭對手追蹤 - 監控活躍的機構、新藥、目標分子和技術
• 加速許可和合作 - 聯繫領先的生物技術開發商、業務拓展和許可專業人士以及學術項目
• 助力高影響力報告和演示 - 利用近乎即時的市場情報推動數據驅動的決策 - 所有數據均可匯出為預置的圖表
• 與關鍵意見領袖 (KOL) 互動 - 與領先的臨床和科學專家建立聯繫
• 尋找合適的投資者 - 利用專注於腫瘤學的融資夥伴網絡
• 掌握產業動態 - 分析全球主要腫瘤學會議（AACR、ASCO、ESMO、ASH 等）的數據

腫瘤學XDC分析工具持續透過持續更新和每月電子郵件提醒，讓您隨時掌握最新動態。

數千種藥物、標靶、公司、臨床試驗、交易等等，盡在您的指尖。

觸手可及的支持與靈感：

將我們的專業知識轉化為您的虛擬業務拓展團隊。我們提供全天候 (24/7) 支持，隨時為您提供協助。我們豐富的操作指南影片庫提供經過驗證的最佳實務。從競爭對手產品線分析到使用者貢獻的案例研究，您將找到可操作的見解來改善您的工作。

與您共同成長的工具：

與提供時間快照的靜態報告不同，我們的分析工具提供一年的線上存取權限。這包括近乎即時的更新、新功能、產品線提醒和專屬支援。

如果您想更進一步，可以無縫續訂或升級到業界領先的全方位服務平台 1stOncology。 1stOncology 是您在癌症藥物研發領域的全面合作夥伴。

系統需求：

• 基於 Web 的應用程序，與主流瀏覽器（Chrome、Firefox、Safari、Internet Explorer）
• 需要網路連接

取得無與倫比的智慧訊息，助力腫瘤藥物研發的策略決策

該工具由屢獲殊榮的人工智慧 (AI) 增強型智慧平台提供支援，該平台擁有超過 25 年的腫瘤學專業知識，可在腫瘤藥物研發的各個階段提供無與倫比的全面業務、競爭和臨床智慧資訊。

在業務拓展和探索/評估方面，它提供了對全球腫瘤領域無與倫比的洞察力，涵蓋從技術、靶點和新創公司到製藥公司、學術和商業機會，並作為一個強大的交易資料庫，整合了許可協議資訊和數千筆歷史交易。

在臨床開發方面，我們擁有業界領先的超過3000種生物標記情報庫，追蹤它們作為分層、預測和藥效學標記物的作用，同時涵蓋從早期到獲批的伴隨診斷工作。我們獨特的早期成功/失敗指標清楚地突出了臨床開發領域的領導者和落後者，幫助您監測和預測不斷變化的市場格局。

我們的臨床試驗情報不僅限於終點，還涵蓋給藥細節、抗藥性機制、不良事件、食物影響、試驗階段和進展、首次人體試驗 (FIH)、腫瘤分期/分級和治療線 (LoT)，從而提供試驗格局的全面視圖。

我們簡化了聯合療法開發的複雜性，將標靶、藥物模式、適應症和試驗階段分解，建構出不斷演進的策略圖譜，從而實現快速的策略決策。

最後，我們將真實世界數據 (RWE) 與針對每個開發階段量身定制的多方面分析相結合。我們的工具涵蓋所有區隔領域——藥物模式、聯合用藥概況、生物標記集群——能夠提供深入的背景洞察，並推動腫瘤研發領域更快、更聰明、更實證的決策。

腫瘤分析工具中偶聯藥物 (XDC) 覆蓋範圍區隔

競爭對手概覽
監測機構數量：	超過 1,200 家
公司	1,061
非營利組織	606
公共組織	352
學術機構	114
新創企業	115
癌症中心/醫院	40
大型製藥/生技公司	36
五大藥物研發公司：	1. Pfizer (incl Seagen) 2. AstraZeneca 3. AbbVie 4. Immunomedics 5. Hangzhou DAC Biotech
排名前五的國家：	1. 美國 2. 中國 3. 英國 4. 加拿大 5. 韓國

研發管線
藥物總數： 發現 臨床前 I期 II期 3 預註冊 商業化 標靶： 腫瘤類型： 臨床試驗： 臨床生物標記： 聯合用藥 療法：	超過 2,500 超過 390 超過 1,370 超過 370 超過 230 83 7 33 478 215 2,426 580 241

交易與合作
過去 5 年的交易數量： 業務拓展與授權聯絡人： 全球學術機構與商業機會：	521 超過 2,400 53

融資與投資人
融資狀況（過去 5 年）： 主要投資者：	超過 1,300 251

The world of conjugated drugs (XDCs) is transforming cancer treatment, unlocking new levels of precision, conditional activation, and therapeutic potential. However, with rapid advancements, fierce competition, and an ever-expanding pipeline, staying ahead requires more than just insights - it demands up-to-date intelligence, strategic foresight, and data-driven decision-making.

In 2024/25 alone, the oncology pipeline saw a surge of innovation, with 436 new conjugated drugs, over 972 drugs with events, and 10,642 total events spanning 2,505 total drug programs - a clear signal of the accelerating pace and complexity in this space.

Introducing the Conjugated Drugs (XDCs) in Oncology Analytical Tool - your comprehensive solution to navigate this dynamic field, track emerging trends, and capitalize on groundbreaking opportunities.

The Ultimate Tool for Exploring What Makes This Field So Exciting:

• XDCs represent a versatile and rapidly evolving class of cancer therapeutics, with at least seven distinct formats - Antibody-Drug Conjugates (ADCs), Peptide-Drug Conjugates (PDCs), Small Molecule-Drug Conjugates (SMDCs), Radioimmunoconjugates (RDCs), Oligonucleotide-Drug Conjugates (ODCs), Nanoparticle-Drug Conjugates, and Enzyme-Drug Conjugates - making this a highly dynamic space to watch as it reshapes the landscape of precision oncology.
• XDC payloads are among the most potent and diverse agents in oncology, including microtubule inhibitors, DNA-damaging agents, topoisomerase inhibitors, radioactive isotopes, immune- and gene modulators - each carefully selected and engineered to maximize tumor killing while minimizing systemic exposure, making payload innovation a critical driver of therapeutic impact and differentiation in the XDC space.
• Linker technology is the molecular lynchpin of XDC performance, enabling precise control over payload release through innovations like cleavable (pH-sensitive, enzyme-sensitive) and non-cleavable linkers. The choice of linker directly impacts stability, pharmacokinetics, and tumor selectivity, making it a strategic lever in optimizing safety, efficacy, and therapeutic index across XDC platforms.
• Conditional activation strategies add a powerful layer of precision to XDCs, enabling payload release specifically in the tumor microenvironment through triggers such as low pH, tumor-associated enzymes, hypoxia, or redox gradients. This tumor-selective activation enhances therapeutic index by minimizing off-target effects and represents a next-generation approach to smarter, safer drug delivery.
• The emergence of bi- and multispecific ADCs marks a new era in targeted therapy, enabling simultaneous engagement of multiple tumor antigens or immune effector pathways. This approach enhances tumor selectivity, overcomes antigen heterogeneity, and opens new opportunities for dual payload delivery or immune system modulation, making it a frontier of innovation in the XDC landscape.

The impact? A rapidly growing clinical pipeline, breakthrough FDA approvals, and a surge in investment opportunities - making the XDC field one of the most exciting frontiers in oncology today.

6 Game-Changing Benefits for You:

With the Conjugated Drugs in Oncology Analytical Tool you will:

• Track the Competitive Landscape - monitor active organizations, new drugs, targets, and technologies
• Accelerate Licensing & Partnerships - access top biotech developers, BD&L contacts, and academic projects
• Power High-Impact Reports & Presentations - fuel data-driven decisions with near real-time market intelligence - all exportable in ready made graphs and tables.
• Engage Key Opinion Leaders (KOLs) - connect with clinical and scientific experts shaping the field
• Find the Right Investors - tap into a network of oncology-focused funding partners
• Stay Ahead of Industry Events - analyze data from top global oncology conferences (AACR, ASCO, ESMO, ASH, and more)

Your Conjugated Drugs (XDCs) in Oncology Analytical Tool is never out of date thanks to continuous updates and monthly email alerts highlighting the latest developments in the field.

You will have thousands of drugs, targets, companies, clinical trials, deals and much more at your fingertips. See below for a breakdown of our near real-time coverage.

Support & Inspiration at Your Fingertips:

Leverage our expertise as your virtual business development team-ready when you are. Our 24/7 support ensures help is always available, while our rich library of How-to Training Videos empowers you with proven best practices. From competitive pipeline analysis to real-world case studies submitted by fellow users, you'll find actionable insights designed to elevate your work.

A Tool That Grows With You:

Unlike static reports that offer just a snapshot in time, our Analytical Tools provide a full year of online access-complete with near real time updates, new features, pipeline alerts, and dedicated support. When you're ready to go further, you can seamlessly renew your access or upgrade to our industry-leading full-service platform: 1stOncology-your comprehensive partner in oncology drug development.

System Requirements:

• Web-based application compatible with all major browsers: Chrome, Firefox, Safari, and Internet Explorer
• Internet access

Secure Your Access to Unrivaled Intelligence for Strategic Decision-Making in Oncology Drug Development

This tool is powered by an award-winning, artificial intelligence (AI) enhanced intelligence platform with over 25 years of expertise in oncology, delivering uniquely comprehensive business, competitive and clinical intelligence across all stages of oncology drug development.

For business development and search & evaluation, it provides unmatched visibility into the global oncology landscape - spanning technologies, targets, start-ups to pharma, and academic-commercial opportunities - making it a powerful deal book with integrated licensing contacts and thousands of past deals.

In clinical development, the tool features an industry-leading biomarker intelligence panel of over 3,000 biomarkers and tracks their roles as stratifying, predictive, and pharmacodynamic markers, alongside companion diagnostic initiatives from early stage to approval. Proprietary early success/failure indicators spotlight clinical leaders and laggards, helping you monitor and and anticipate shifts in the evolving landscape.

Our clinical trial intelligence goes beyond endpoints, capturing dosage details, resistance mechanisms, adverse events, food effects, trial phase and status progression, first-in-human (FIH) studies, tumor stage/grade, and line of therapy (LoT) - offering a complete view of the trial landscape.

We simplify the complexity of combination therapy development, breaking down targets, drug modalities, indications, and trial stages to create a map of evolving strategies for fast, strategic decision-making.

Finally, we integrate Real-World Evidence (RWE) with multi-point analytics tailored to any development stage. Whether segmented by drug modality, co-medication profiles, or biomarker clusters, the tool enables deep, contextual insights - driving faster, smarter, and evidence-based decisions in oncology research and development.

Coverage Breakdown from your Conjugated Drugs (XDCs) in Oncology Analytical Tool

Competitor Overview
Organizations Monitored:	1,200+
Organization Types:      Corporate      Private      Public      Academic      Startup      Cancer Ctr/Hospital      Big Pharma/Biotech	1,061 606 352 114 115 40 36
Top 5 Drug Developers:	1. Pfizer (incl Seagen) 2. AstraZeneca 3. AbbVie 4. Immunomedics 5. Hangzhou DAC Biotech
Top 5 Nations:	1. USA 2. China 3. UK 4. Canada 5. South Korea

Pipeline
Total No Drugs:     Discovery     Preclinical     Phase 1     Phase 2     Phase 3     Pre-registration     Marketed Targets: Tumor Types: Clinical Trials: Clinical Biomarkers: Drugs in Combination Therapies:	2,500+ 390+ 1370+ 370+ 230+ 83 7 33 478 215 2,426 580 241

Deals & Alliances
No. Deals (Last 5 Years): BD&L Contacts: World-Wide Academic Commercial Opportunity Projects:	521 >2,400 53

Funding & Investors
Funding (Last 5 Years): Top Investors:	>1,300 251